Insiders who reported open-market trades in the last 12 months at the companies Naimish Patel files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
David R. Epstein - $131K in AGMB purchases and sales in the last 12 months
Naimish Patel is a corporate insider, tracked as Director of AgomAb Therapeutics NV (AGMB). InsiderAlpha holds 8 primary Form 4 filings for them, the earliest from 2024, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Naimish Patel submitted recently?
1 primary Form 4 filing in the last 90 days, covering 1 company.
Has Naimish Patel been buying or selling stock?
Recorded transactions: 1 open-market purchase ($50K) and 2 open-market sales ($363K) across all tracked filings.
Naimish Patel is Director of AgomAb Therapeutics NV (AGMB). 8 SEC Form 4 filings on record going back to 2024, most recently on 15 September 2026. Most recent open-market trade: sold $211K of CRSP on 1 June 2026. Lifetime open-market purchases: $50K. Lifetime open-market sales: $363K.
Recent transactions
5
The latest 5 SEC Form 4 transactions reported by Naimish Patel.
InsiderAlpha's records for Naimish Patel go back to 2024: 8 primary Form 4 filings, an average of 2.7 per year. The typical open-market purchase is $50K (1 buy totaling $50K). The largest single buy on record is $50K of CRSP in 2026. Sales side: 2 recorded sales totaling $363K, so the filing history runs sell-heavy by dollar value. No recorded transaction carries a Rule 10b5-1 plan flag. An absent flag does not establish whether a transaction was pre-arranged or discretionary.
